[ad_1]
Shareholders of Somerset Healthcare Catalent The acquisition has been approved Novo HoldingsThe company, which is the parent of Novo Nordisk, announced the news on Wednesday.
trade, First announced in Februaryvaluing the company at $63.50 per share in cash, or about $11 billion — or $16.5 billion including debt.
Novo’s North American headquarters are in Plainsboro.
“Today’s results represent an important step toward the closing of this transaction, and we thank our shareholders for their strong support and confidence in Catalent’s future,” said Alessandro Maselli, CEO and president, in a prepared statement. “Following the close of the transaction, we look forward to writing the next chapter for Catalent, benefiting from the expertise and resources of Novo Holdings as we continue to be a leading independent (contract development and manufacturing organization) worldwide that develops, manufactures and supplies products that help people live better, healthier lives.”
The transaction is expected to close by the end of the year, subject to customary conditions and approvals.
[ad_2]
Source link
